Eli Lilly and Company

September 03, 2026 – INDIANAPOLIS -- Eli Lilly and Company reported that combining Taltz (ixekizumab) with Zepbound (tirzepatide) sustained or deepened efficacy at 52 weeks in patients with psoriatic disease and obesity, building on statistically superior results already seen at Week 36 versus Taltz alone.

Combination therapy nearly triples complete skin clearance response rates

In the TOGETHER-PsO trial, 30.6% of patients on the combination achieved PASI 100 plus at least 10% weight loss at Week 52, compared with 4.4% on Taltz monotherapy. Complete skin clearance alone (PASI 100) was maintained by 40.5% of combination patients versus 29.1% on monotherapy.

INDIANAPOLIS and CAMBRIDGE, Mass. -- Aug. 31, 2026 -- Eli Lilly and Company agreed to pay up to $2.875 billion in cash to acquire Merida Biosciences, a Cambridge, Massachusetts-based biotechnology company developing antibody-degrading therapies for autoimmune and allergic diseases. The figure includes an upfront payment plus contingent milestone payments under a definitive agreement announced by both companies. The transaction is subject to customary closing conditions, including regulatory approvals, and is expected to close in the fourth quarter of 2026.